SAN FRANCISCOâ€”Two patients with a lethal blood disorder have been able to forgo life-sustaining blood transfusions for at least five months after being treated with a technique to replace the defective gene responsible for their disease, researchers said Monday.. The results, reported at the annual meeting of the American Society of Hematology, mean a total of five patients have now experienced durable correction of their disease with a gene therapy being developed by bluebird bio Inc., a biotechnology company in Cambridge,...
  